Capital Wealth Planning LLC Purchases 8,746 Shares of Cencora, Inc. $COR

Key Points

• Capital Wealth Planning LLC increased its Q3 stake in Cencora by 156%, purchasing 8,746 shares to hold 14,351 shares worth about $4.485 million.
• Insiders have been net sellers — 15,220 shares were sold over the last three months worth $5.28 million (including EVP Elizabeth Campbell's 3,351-share sale and Silvana Battaglia's 1,677-share sale), leaving insiders with just 0.38% ownership.
• Analyst consensus is a "Moderate Buy" with a $399 target; Cencora recently reported $4.08 EPS (beat) and $85.93 billion revenue (slightly below estimates).

Capital Wealth Planning LLC lifted its position in Cencora, Inc. (NYSE:COR - Free Report) by 156.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,351 shares of the company's stock after purchasing an additional 8,746 shares during the quarter. Capital Wealth Planning LLC's holdings in Cencora were worth $4,485,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. IAG Wealth Partners LLC bought a new stake in Cencora in the 3rd quarter valued at $30,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock worth $31,000 after acquiring an additional 43 shares during the period. Cloud Capital Management LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at about $31,000. Caitlin John LLC bought a new stake in Cencora in the third quarter valued at about $31,000. Finally, Westside Investment Management Inc. increased its stake in Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company's stock valued at $33,000 after acquiring an additional 70 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company's stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company's stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of analyst reports. Bank of America cut their price target on shares of Cencora from $380.00 to $360.00 and set a "neutral" rating for the company in a research note on Monday, January 5th. Evercore lowered their price objective on Cencora from $440.00 to $420.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. Wall Street Zen cut Cencora from a "buy" rating to a "hold" rating in a report on Friday, November 28th. Barclays boosted their price target on Cencora from $400.00 to $425.00 and gave the company an "overweight" rating in a research note on Friday, February 13th. Finally, Weiss Ratings upgraded Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $399.00.

Cencora Stock Performance

Shares of Cencora stock opened at $349.69 on Friday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm has a 50 day simple moving average of $355.58 and a 200 day simple moving average of $338.13. Cencora, Inc. has a fifty-two week low of $252.49 and a fifty-two week high of $377.54. The firm has a market cap of $68.03 billion, a P/E ratio of 42.03, a P/E/G ratio of 1.64 and a beta of 0.68.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analysts' expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm's quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business earned $3.73 earnings per share. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora's dividend payout ratio is presently 28.85%.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.